Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.
You may also be interested in...
Protease Inhibitors Line Up To Challenge Vertex In HCV
In-class skirmish likely as combo therapy evolves, analyst tells “The Pink Sheet” DAILY.
Protease Inhibitors Line Up To Challenge Vertex In HCV
In-class skirmish likely as combo therapy evolves, analyst tells “The Pink Sheet” DAILY.
Abbott Wins Rights To Enanta’s Preclinical HCV Protease Inhibitors
Collaboration moves Abbott into an increasingly competitive area of research.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: